An interventional study of carbon ion radiation therapy CIRT in Malignant Melanoma and Gynecologic Cancer, sponsored by CNAO National Center of Oncological Hadrontherapy. Recruiting at 1 site in Italy. Open to female participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-21.
Sponsored by CNAO National Center of Oncological Hadrontherapy · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 268 studies in Melanoma with a site in Italy — 47 open to participants now, 80 under way, 22 of them phase 3. Melanoma · Italy.
Among the 268 studies in Melanoma with a site in Italy, this one is the 229th largest by planned enrollment of the 236 interventional ones that give a count, is one of 17 that started in 2020, is one of 20 with no phase, reaches primary completion later than 47 of the 79 other live ones, and was the 197th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →47 of the 268 studies in Melanoma with a site in Italy are open now. Recruiting first, the newest first:
European Institute of Oncology · Sites in Italy
Ages 18+
Bristol-Myers Squibb · Sites in Italy, United States, Belgium and 10 more countries
Ages 18+
IDEAYA Biosciences · Sites in Italy, United States, Australia and 18 more countries
Ages 18+
mAbxience Research S.L. · Sites in Italy, Bosnia and Herzegovina, Brazil and 10 more countries
Ages 18+
Ente Ospedaliero Ospedali Galliera · Sites in Italy
Ages 18–39
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
268 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 106 · Phase 3 79 · Phase 4 1
First in 1995; this study’s year is marked. 17 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 191 across the 236 interventional studies, 270 across the 31 observational. Of the 166 that completed or were terminated, 92 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
191 of 268 have an industry lead sponsor. The 10 most frequent:
CNAO National Center of Oncological Hadrontherapy is the lead sponsor of 11 studies on the registry; 8 are open to participants now.
CNAO National Center of Oncological Hadrontherapy has 2 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
24 of the studies in Melanoma with a site in Italy that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT07221734Phase 3mAbxience Research S.L.Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | 2027-04 |
| NCT05522660Phase 3ETOP IBCSG Partners FoundationImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer | 2027-06 |
Add all 24 to your calendar (.ics) → With an account.
Among the 268 studies in Melanoma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present monocentric prospective phase 2 study aims to reproduce the results obtained at NIRS thus offering the possibility of obtaining a promising rate of progression-free survival (PFS) and local control (LC) in patients diagnosed with mucosal melanoma of lower genital tract. Systemic treatment with immunotherapy is not the subject of this study but is allowed both in the neoadjuvant and sequential regimens.
Melanomas have always been considered poorly radiosensitive. It is now accepted that high LET (Linear Energy Transfer) particle beams, such as carbon ions, can offer a biological advantage, compared to photons treatment, in radio-resistant neoplasms treatment, thanks to their higher biological efficacy (RBE) against tumours with a low α/ ß ratio. In addition, carbon ions have the physical advantage of an inverted depth deposition profile compared to photons, allowing then a steep dose gradients that ensure increased sparing of adjacent healthy organs at risk (OARs).
Patients with primary gynaecological melanoma, non-metastatic, non-suitable for surgery, and not previously subjected to conventional radiotherapy can be enrolled in the trial, according to selection criteria. After requested baseline exams, the patient undergoes to simulation phase for the carbon ion radiation therapy, according to study constraints. The patient will then receive immunotherapy not concomitant to CIRT. The response is evaluated through RECIST criteria.
PFS is the primary endpoint, calculated from the end of CIRT to date of disease progression or death or last follow up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients affected by pelvic recurrence of gynecological cancer, who had not undergone to previous pelvic irradiation, will be enrolled on this study. After enrollment, patients undergo baseline exams, simulation CT and MRI and then carbon ion radiation therapy treatment will be performed, according to trial indications.
Radiation: carbon ion radiation therapy CIRT
CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week. The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable. Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol.
Also known as: immunotherapy
progression free survival
estimate 2-year PFS in patients diagnosed with mucosal melanoma of the lower genital tract, treated with carbon ion radiation therapy.
Time frame: 2 years
Overall survival (OS)
The OS will be calculated from the end date of therapy with carbon ion radiation
Time frame: 3 years
Toxicity according to Common Terminology Criteria for Adverse Events (CTCAE version 5.0)
acute, medium term and late toxicity
Time frame: within 3 months, 3-6 months, over 6 months from CIRT
local response
according to Response Evaluation Criteria in Solid Tumours RECIST 1.1
Time frame: 3 years
assessment of quality of life
assessed through questionarie Portec 3 administered on each follow up
Time frame: 3 years
assessment of quality of life for >= 75 years old patients
assessed through questionnaire G8 Geriatric questionnaire administered on each follow up
Time frame: 3 years
Started Sep 2020 (actual). Primary completion is estimated for Sep 2027, 84 months after the start.
Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 84 months is above that.
Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CNAO National Center of Oncological Hadrontherapy